Amgen Looks To Enter Multiple Myeloma Space: Can It Compete? [Seeking Alpha]
bluebird bio, Inc. (BLUE)
Last bluebird bio, inc. earnings: 2/18 04:05 pm
Check Earnings Report
US:NASDAQ Investor Relations:
investor.bluebirdbio.com/investor-overview
Company Research
Source: Seeking Alpha
Summary Amgen announces positive preliminary results using its antibody drug known as AMG 420, which is derived from the anti-BCMA BiTE program. AMG 420 is a drug that acts as a bridge for two proteins, which are BCMA and CD3, against tumors; this unique approach may offer a competitive advantage. It was shown that 5 stringent complete responses were achieved for those relapsed/refractory multiple myeloma patients that were treated with AMG 420. At least 4 out of 5 patients treated with AMG 420 were MRD-negative, meaning they had no detectable form of disease after treatment. Recently, Amgen ( AMGN ) announced positive preliminary results from its study treating patients with relapsed/refractory multiple myeloma. Early indications are highly positive, and I believe that this company could end up being a strong contender in this space. Early data shows that a majority of patients treated with AMG 420 achieved a stringent complete response. While this data is early in n
Show less
Read more
Impact Snapshot
Event Time:
BLUE
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
BLUE alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
BLUE alerts
High impacting bluebird bio, Inc. news events
Weekly update
A roundup of the hottest topics
BLUE
News
- bluebird bio, Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky Before May 28, 2024 to Discuss Your Rights - BLUEAccesswire
- bluebird bio, Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky for More Information - BLUEAccesswire
- Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against bluebird bio, Inc. (BLUE)GlobeNewswire
- bluebird bio, Inc. Securities Fraud Class Action Lawsuit Pending: Contact Levi & Korsinsky Before May 28, 2024 to Discuss Your Rights - BLUEAccesswire
- bluebird bio, Inc. Class Action: Levi & Korsinsky Reminds bluebird bio Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of May 28, 2024 - BLUEAccesswire
BLUE
Earnings
- 11/7/23 - Beat
BLUE
Sec Filings
- 5/9/24 - Form 8-K
- 5/3/24 - Form 8-K
- 4/26/24 - Form 8-K
- BLUE's page on the SEC website